Compare · EVOK vs JNJ
EVOK vs JNJ
Side-by-side comparison of Evoke Pharma Inc. (EVOK) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVOK and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $651.20B, about 38348.1x EVOK ($17.0M).
- Over the past year, EVOK is up 113.4% and JNJ is up 54.0% - EVOK leads by 59.4 points.
- JNJ has hit the wire 13 times in the past 4 weeks while EVOK has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 0 for EVOK).
- Company
- Evoke Pharma Inc.
- Johnson & Johnson
- Price
- $10.99+0.37%
- $268.38-0.69%
- Market cap
- $17.0M
- $651.20B
- 1M return
- +2.81%
- -1.85%
- 1Y return
- +113.40%
- +54.05%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2013
- News (4w)
- 0
- 13
- Recent ratings
- 0
- 25
Evoke Pharma Inc.
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest EVOK
- SEC Form 15-12G filed by Evoke Pharma Inc.
- Large owner Nantahala Capital Management, Llc disposed of $1,629,683 worth of shares (148,153 units at $11.00) (SEC Form 4)
- SEC Form EFFECT filed by Evoke Pharma Inc.
- SEC Form EFFECT filed by Evoke Pharma Inc.
- SEC Form EFFECT filed by Evoke Pharma Inc.
- SEC Form EFFECT filed by Evoke Pharma Inc.
- SEC Form EFFECT filed by Evoke Pharma Inc.
- SEC Form EFFECT filed by Evoke Pharma Inc.
- SEC Form S-8 POS filed by Evoke Pharma Inc.
- SEC Form S-8 POS filed by Evoke Pharma Inc.
Latest JNJ
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
- Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
- SEC Form 4 filed by Director Pinto Daniel E
- SEC Form 4 filed by Director Woods Eugene A.
- SEC Form 4 filed by Director Hewson Marillyn A
- Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
- Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
- EVP, WW Chair, MedTech Schmid Timothy exercised 33,597 shares at a strike of $144.99 and sold $9,230,440 worth of shares (33,597 units at $274.74) (SEC Form 4)
- Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
- UBS resumed coverage on Johnson & Johnson with a new price target